Barclays PLC Increases Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Barclays PLC increased its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 20.1% in the third quarter, Holdings Channel.com reports. The fund owned 64,423 shares of the medical equipment provider’s stock after buying an additional 10,803 shares during the quarter. Barclays PLC’s holdings in BioLife Solutions were worth $1,613,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of BLFS. Mutual of America Capital Management LLC purchased a new position in shares of BioLife Solutions during the second quarter worth approximately $8,592,000. Rockefeller Capital Management L.P. grew its stake in BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after purchasing an additional 262,504 shares in the last quarter. State Street Corp increased its holdings in BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares during the period. Envestnet Asset Management Inc. raised its position in BioLife Solutions by 261.5% during the 2nd quarter. Envestnet Asset Management Inc. now owns 127,215 shares of the medical equipment provider’s stock valued at $2,726,000 after purchasing an additional 92,021 shares in the last quarter. Finally, Fred Alger Management LLC lifted its holdings in shares of BioLife Solutions by 6.0% in the 2nd quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock worth $33,841,000 after buying an additional 88,840 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Price Performance

Shares of BLFS opened at $26.61 on Friday. The company has a 50 day moving average of $26.04 and a two-hundred day moving average of $24.35. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a twelve month low of $14.50 and a twelve month high of $28.88. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -25.10 and a beta of 1.92.

Insider Activity

In other BioLife Solutions news, EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $23.28, for a total transaction of $232,800.00. Following the transaction, the executive vice president now owns 317,716 shares in the company, valued at approximately $7,396,428.48. This represents a 3.05 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Troy Wichterman sold 987 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the transaction, the chief financial officer now directly owns 121,779 shares of the company’s stock, valued at approximately $3,290,468.58. This represents a 0.80 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 113,129 shares of company stock worth $2,576,818. Insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BLFS shares. TD Cowen upped their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright lowered their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Benchmark reissued a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. Craig Hallum increased their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, KeyCorp lifted their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.43.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.